- Recruiting
NCT03909412: Phase 1: Carfilzomib Based Chemotherapy Mobilization for ASCT in Myeloma (CarMob)
NCT03909412: Phase 1: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (CarMob)
NCT03909412: Phase 1: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (CarMob)
This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulating factor (G-CSF)
Sponsor
Hackensack Meridian Health
Collaborator
ClinicalTrials.gov Identifier: NCT03909412
Official Title: Phase I Study of Carfilzomib-based Chemotherapy Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma
First Posted : April 10, 2019
Click here to see details on ClinicalTrials.gov
Drug: Carfilzomib
Drug: Cyclophosphamide
Drug: Dexamethasone
Drug: Granulocyte Colony-Stimulating Factor
Location
United States, New Jersey
Hackensack Meridian Health - John Theurer Cancer Center